Structure Therapeutics (NASDAQ:GPCR) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Structure Therapeutics (NASDAQ:GPCR) from a hold rating to a sell rating in a report released on Saturday morning.

GPCR has been the subject of several other research reports. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Wolfe Research initiated coverage on Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Morgan Stanley boosted their price target on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Jefferies Financial Group set a $125.00 price objective on shares of Structure Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, HC Wainwright cut their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $110.00.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $43.94 on Friday. The firm has a market capitalization of $3.11 billion, a P/E ratio of -55.62 and a beta of -1.79. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90. The company’s fifty day moving average price is $67.90 and its 200-day moving average price is $51.98.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently bought and sold shares of the business. CWM LLC increased its position in shares of Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares in the last quarter. State of Wyoming purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Structure Therapeutics in the 4th quarter valued at $127,000. Finally, Banque Cantonale Vaudoise acquired a new stake in Structure Therapeutics in the 4th quarter valued at $205,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.